Drug Profile

MTL HBG

Alternative Names: MTL-HBG

Latest Information Update: 18 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MiNA Therapeutics
Class Antianaemics; RNA
Mechanism of Action Fetal haemoglobin expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

12 Jun 2025 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Sickle cell anaemia released by MiNA Therapeutics
11 Dec 2024 MiNA Therapeutics has patents pending for MTL HBG in (MiNA Therapeutics website; December 2024)
07 Dec 2024 MTL HBG is available for licensing as of 07 Dec 2024. https://minatx.com/about/partners/ (MiNA Therapeutics website; December 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com